Log in to post a reply
Sep 16, 2019 02:01PM
Michelle, the Oncotype DX test for invasive breast cancer is very different from the Oncotype test for DCIS (unfortunate that the tests have the same name). The invasive cancer test has been around longer and has been incorporated into invasive cancer treatment protocols. That is not the case with the Oncotype DX test for DCIS.
Lisa, I recall that when the Oncotype DX for DCIS first came out, there were questions as to whether it should be used when the DCIS is grade 3 because the patient group involved in the original test validation was quite small.
A Multigene Expression Assay to Predict Local Recurrence Risk for Ductal Carcinoma In Situ of the Breast
More studies have been done since which seem to support it's use, although frankly it seems that the Oncotype DX for DCIS has never really gotten off the ground. From reading here, it seems to rarely be suggested by doctors but more often is requested by patients. Some of the other studies/articles:
SABCS 2014: Oncotype DX DCIS Score Reliably Predicts Breast Cancer Recurrence in Patients With DCIS
- Study abstract referenced by SABCS 2014: [S5-04] A large prospectively-designed study of the DCIS score: Predicting recurrence risk after local excision for ductal carcinoma in situ patients with and without irradiation
A population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by breast-conserving surgery alone.
Abstract P5-18-12: Effectiveness of Oncotype DX DCIS scoring in a community setting
“No power so effectually robs the mind of all its powers of acting and reasoning as fear.” Edmund Burke